ASND•benzinga•
JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $200
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 18, 2025 by benzinga